December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

13.17 +1.05 (+8.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,625,531
Open 12.21
Bid (Size) 13.17 (30)
Ask (Size) 13.18 (295)
Prev. Close 12.12
Today's Range 12.07 - 13.30
52wk Range 6.550 - 13.54
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis
Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy. 
Via Chartmill
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
+50.2%
+50.2%
1 Month
+19.2%
+19.2%
3 Month
+42.5%
+42.5%
6 Month
+60.6%
+60.6%
1 Year
+78.9%
+78.9%

More News

Read More
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery
Via Stocktwits
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For July 31, 2025
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
Via Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Via Investor's Business Daily
Topics ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria
Via Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
Via Investor's Business Daily
Aurinia (AUPH) Q2 Revenue Jumps 22%
Via The Motley Fool
Topics Intellectual Property
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results
Via Stocktwits
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
Via Benzinga
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Via Benzinga

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 13.17
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 10/31/25 04:00 PM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 1.69B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.